Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979316 · ClinicalTrials.gov registry record · Phase 1
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT00979316 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 62 participants.
The verdict
NCT00979316, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG BMS-708163
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979316
The ClinicalTrials.gov registry entry for NCT00979316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00979316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00979316 about?
NCT00979316 is a clinical study titled "Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects". The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).
What is the current status of trial NCT00979316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2009-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00979316?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), BMS-708163 (DRUG).
Who is sponsoring clinical trial NCT00979316?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.